MJ Hayes, F Qing, CG Rhodes, SU Rahman, PW Ind, S Sriskandan, T Jones and JM Hughes
Medical Research Council, Clinical Sciences Center, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

In human subjects, chronic beta2-agonist dosing reduces mononuclear leukocyte (MNL) beta-adrenoceptor numbers. The aim of this study was to investigate whether this downregulation also occurs in the lung. Seven healthy male subjects were treated for 2 wk with oral (up to 16 mg/d) and inhaled (up to 1.6 mg/d) albuterol (salbutamol in Europe). Pulmonary maximal beta-adrenoceptor binding capacity (Bmax) was determined in vivo using positron emission tomography (PET) and the beta-receptor antagonist ligand, 11C-labeled CGP-12177, before and after the 2-wk chronic dosing. MNL Bmax was also measured, using a radioligand binding assay and 3H-labeled CGP-12177. Bronchodilator responses to the beta2-agonist were determined after each PET scan by measuring the change in specific airway conductance (SGaw) after increasing doses of inhaled albuterol. Pulmonary and MNL Bmax fell by 22% +/- 14% (p < 0.05) and 42% +/- 19% (p < 0.05) respectively. The changes in pulmonary and MNL Bmax were correlated (r = 0.9, p < 0.05). There was also a reduction in the bronchodilator response to inhaled albuterol. In a further six subjects, pulmonary and MNL Bmax did not change during an acute infusion of albuterol (2 to 4 microg/kg/h). The reduction in pulmonary beta-adrenoceptor numbers after chronic albuterol dosing may be predictable from the changes observed in circulating MNL cells.

This article has been cited by other articles:

				A. van Waarde, B. Maas, P. Doze, R. H. Slart, H. W. Frijlink, W. Vaalburg, and P. H. Elsinga Positron Emission Tomography Studies of Human Airways Using an Inhaled {beta}-Adrenoceptor Antagonist, S-11C-CGP 12388 Chest, October 1, 2005; 128(4): 3020 - 3027. [Abstract] [Full Text] [PDF]

				L. Brichetto, M. Milanese, P. Song, M. Patrone, E. Crimi, K. Rehder, and V. Brusasco Beclomethasone rapidly ablates allergen-induced beta 2- adrenoceptor pathway dysfunction in human isolated bronchi Am J Physiol Lung Cell Mol Physiol, January 1, 2003; 284(1): L133 - L139. [Abstract] [Full Text] [PDF]

				A Kamachi, M Munakata, Y Nasuhara, M Nishimura, Y Ohtsuka, M Amishima, T Takahashi, Y Homma, and Y Kawakami Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma Thorax, January 1, 2001; 56(1): 19 - 24. [Abstract] [Full Text]

				L. GROTE, H. KRAICZI, and J. HEDNER Reduced alpha - and beta 2-Adrenergic Vascular Response in Patients with Obstructive Sleep Apnea Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1480 - 1487. [Abstract] [Full Text] [PDF]

				I. Aziz and B. J. Lipworth A Bolus of Inhaled Budesonide Rapidly Reverses Airway Subsensitivity and {beta}2-Adrenoceptor Down-regulation After Regular Inhaled Formoterol Chest, March 1, 1999; 115(3): 623 - 628. [Abstract] [Full Text] [PDF]

				B. J. Lipworth, I. P. Hall, S. Tan, I. Aziz, and W. Coutie Effects of Genetic Polymorphism on Ex Vivo and In Vivo Function of {beta}2-Adrenoceptors in Asthmatic Patients Chest, February 1, 1999; 115(2): 324 - 328. [Abstract] [Full Text] [PDF]

				M. JOHNSON The beta -Adrenoceptor Am. J. Respir. Crit. Care Med., November 1, 1998; 158(2007): S146 - S153. [Abstract] [Full Text] [PDF]

				M. I. ANSTEAD, T. A. HUNT, S. L. CARLSON, and N. K. BURKI Variability of Peripheral Blood Lymphocyte Beta-2-Adrenergic Receptor Density in Humans Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 990 - 992. [Abstract] [Full Text] [PDF]

				G. Gauvreau, M Jordana, R. Watson, D. Cockroft, and P. O'Byrne Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1738 - 1745. [Abstract] [Full Text]